FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCoherus Oncology, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CHRS
Coherus Oncology, Inc. Stock AnalysisComprehensive stock analysis for Coherus Oncology, Inc. (CHRS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCHRS
CHRS
Coherus Oncology, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CHRS
  1. Home
  2. Stocks
  3. Coherus Oncology, Inc.

Coherus Oncology, Inc.

🇺🇸CHRS•NASDAQ

Coherus Oncology, Inc.

🇺🇸CHRS•NASDAQ
Market cap
$57.15M

Your view on CHRS

Mkt Cap
$57.15M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Coherus Oncology, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Dennis M. Lanfear
Headquarters
333 Twin Dolphin Drive, Redwood City, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Dennis M. Lanfear
Headquarters
333 Twin Dolphin Drive, Redwood City, CA, US
Description

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.

It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.

In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited.

The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Coherus Oncology, Inc.. Starting points for Coherus Oncology, Inc.: EPS -$0.87, beta 1.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Coherus Oncology, Inc.. Trailing twelve-month EPS for Coherus Oncology, Inc. stands at -$0.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Coherus Oncology, Inc.. Coherus Oncology, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CHRS12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
CAICaris Life Sciences, Inc.HealthcareNASDAQ$5.0B
CAIHFChia Tai Enterprises International LimitedHealthcareOTC$217.4M
CALACalithera Biosciences, Inc.HealthcareOTC$974
CALCCalciMedica, Inc.HealthcareNASDAQ$4.0M
CAMPCAMP4 Therapeutics CorporationHealthcareNASDAQ$237.8M
CAMRFCamurus AB (publ)HealthcareOTC$3.5B
CANFCan-Fite BioPharma Ltd.HealthcareAMEX$1.9M
CAPRCapricor Therapeutics, Inc.HealthcareNASDAQ$439.6M
CARMCarisma Therapeutics, Inc.HealthcareNASDAQ$2.4M
CASBFCanSino Biologics Inc.HealthcareOTC$1.3B
CASIFCASI Pharmaceuticals, Inc.HealthcarePNK—
CBDGTHC Farmaceuticals, Inc.HealthcareOTC$797,790
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Coherus Oncology, Inc., and how their positions are changing. At a $57.1M market value, institutional positions materially move Coherus Oncology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Coherus Oncology, Inc. executives and directors. Shares of Coherus Oncology, Inc. have traded between $0.71 and $2.43 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Coherus Oncology, Inc.. Coverage tracks Coherus Oncology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Coherus Oncology, Inc.

CHRS AnalysisFair
Past
1
Growth
1
Health
2
Profit
5
Value
1